Mollugin enhances the osteogenic action of BMP-2 via the p38-Smad signaling pathway
- Arch Pharm Res. 2017 Nov;40(11):1328-1335. doi: 10.1007/s12272-017-0964-4.
- 1. Bio & Drug Discovery Division, Center for Drug Discovery Technology, Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon, 334114, Republic of Korea.
- 2. Department of Biology, Chungnam National University, Daejeon, Republic of Korea.
- 3. Department of Strategy and Planning, Korea Institute of Science and Technology Information, Seoul, Republic of Korea.
- 4. College of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon, 21983, Republic of Korea. [email protected].
- 5. Bio & Drug Discovery Division, Center for Drug Discovery Technology, Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon, 334114, Republic of Korea. [email protected].
Bone Morphogenetic Protein 2 (BMP-2) has been used clinically to encourage bone regeneration; although, there can be major side effects with larger doses. Therefore, there is a need to identify new small molecules to potentiate the osteogenic action of BMP-2. In this study, we investigated the effect of mollugin on bone formation in murine bi-potential mesenchymal progenitor C2C12 cells by combination with BMP-2. We found mollugin could enhance the BMP-2-mediated osteoblast differentiation of C2C12 cells. This was accompanied by the induction of Other osteogenic BMPs. We also found the enhancing potential of mollugin may involve activation of the p38-Smad1/5/8 signaling axis. Furthermore, mollugin promoted skeletal development in zebrafish. The combination of BMP-2 with small molecules, including mollugin, could minimize its clinical limitations, and these molecules might lead to the development of effective stem cell stimulants for bone regeneration and fracture healing.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Cancer